Securing America’s Medicines and Supply (SAMS)

SAMS is a multi-industry coalition of companies with the mission to strengthen the security of the medical supply chain in the United States.

Introduction

SAMS seeks to drive implementation of legislation and regulation to reward and foster U.S.-made manufacturing of important pharmaceutical products, devices, and personal protection equipment. We support U.S. patients, domestic healthcare security, and U.S. jobs. Specific policy initiatives include:

  • Encourage increased manufacturing operations within U.S. borders for the U.S. medical supply chain via reforms to trade and tax law to design policies that promote domestic production.
  • Maintain and expand U.S. government loan, grant, direct investment, and purchase agreement programs for important medical infrastructure developed by companies primarily manufacturing in the United States through the National Institutes of Health (NIH) and Biomedical Advanced Research Development Authority (BARDA).
  • Explore opportunities within Medicare, the Veterans Administration, and the Department of Defense to recognize and promote U.S.-made pharmaceutical products and supplies.
  • Strengthen procurement to the strategic national stockpile (SNS) for important pharmaceuticals, diagnostics, medical devices, and personal protective equipment, with emphasis on those produced domestically.
Members
Coherus BioSciences
Coherus is an American-made, commercial stage biopharmaceutical company with the mission to increase access to cost-effective biosimilar and innovative medicines that can deliver a major impact on patients’ lives and savings to the health care system.
iRemedy
With 15 years in healthcare supply, iRemedy is a trusted and reliable partner for acquiring medical equipment and supplies. We service over 10,000 hospitals, surgery centers, physicians, commercial and government clients nationwide. For more information, please visit www.iRemedy.com.
Teva Pharmaceuticals USA, Inc.
Teva Pharmaceuticals is a global pharmaceutical company headquartered in Tel Aviv, Israel that specializes in the manufacture of generic drugs, research and development of novel therapies and pharmaceutical distribution. Teva is the largest generic drug manufacturer in the world, with manufacturing facilities concentrated in the United States, Europe, and Israel. Anda, a wholly-owned subsidiary of Teva, is the fourth-largest drug distributor in the United States. 
US Biologic
US Biologic® is a social innovation company that “Delivers Disease Prevention®.” The company’s proprietary OrisBioSM oral-delivery platform is changing global disease prevention, allowing safe, effective, and cost-efficient preventative therapeutics for wildlife, companion animals, and food animals.
Zymergen
Zymergen is a biofacturing company using biology to make better products in a better way. Zymergen partners with nature to create, develop, and manufacture breakthrough products and materials in electronics, agriculture, consumer care, and beyond. Learn more at zymergen.com.
Board of Directors
Denny M. Lanfear
SAMS Chairman
CEO and Chairman, Coherus BioSciences
Denny Lanfear is a biopharmaceutical leader and biosimilar pioneer with a proven track record of successful entrepreneurial vision and achievement. In 2010, after decades working in the biopharmaceutical industry, he founded Coherus BioSciences with the vision of improving the public’s access to high-quality, life-changing medicines. Under Mr. Lanfear’s leadership as CEO and Chairman, Coherus BioSciences has transformed from an unfunded startup into the industry’s leading pure play biosimilar company. In addition, he has led its foray into innovative cancer therapeutics in 2021.
George Keefe
SAMS Treasurer
Senior Vice President of External Affairs and Public Policy, Teva Pharmaceuticals
George Keefe has more than 25 years in the biopharmaceutical industry. His leadership roles includes Government Affairs, Public Policy, Market Access, Payer Marketing, Pricing and Contracting, Medical Affairs and Sales. He joined in 2002 and is currently a Board member at the Association for Accessible Medicines (AAM) where he serves on the Executive Committee and is leading the Quality and Overseas Manufacturing Task Force which recently published “A Blueprint for Enhancing the Security of the U.S. Pharmaceutical Supply Chain.”

George holds a bachelor’s degree in economics with a minor in political science from SUNY Geneseo and an MBA from the University at Buffalo. He lives in Santa Rosa Beach, Florida with his wife Linda and dog Smitty.
David T. Sanders
SAMS Executive Director
Vice President, Government Affairs and Policy, Coherus BioSciences
David Sanders has more than twenty years of experience working in government and industry. He worked for Senator Fred Thompson (R-TN), then-Representative Marsha Blackburn (R-TN), and Bush-Cheney 2004. He served as a legislative liaison for the U.S. Patent and Trademark Office, working on intellectual property and trade law. He advanced policy working for Teva Pharmaceuticals USA, National Community Pharmacists Association and DaVita Inc. before joining Coherus BioSciences in the summer of 2020 where he leads a small team in policy, advocacy and public affairs.
Anna Osterlind
SAMS Director
Head of Government Affairs, Zymergen
Anna Osterlind is Head of Government Affairs at Zymergen, where she leads the company’s engagement with the Administration and Congress. She rejoined the company in 2021, having previously worked at Zymergen from 2015 to 2018 as the then-startup grew from 40 to nearly 500 employees. Prior to her current position, Anna served in multiple roles with the United States Department of Agriculture, where she helped launch the domestic hemp industry among other initiatives. She started her career on Capitol Hill in the office of Senator Roy Blunt from her home state of Missouri.
Stephen R. Conafay
SAMS Secretary and Washington Counsel
Steve Conafay has 35 years of leadership and management experience in government relations, public policy and communications. For 12 years, Mr. Conafay was vice president of government relations for Pfizer, where he was elected as a corporate officer in 1984. He served as senior vice president of corporate affairs for Glaxo Inc., where he was also a member of the Board of Directors. After heading the legislative practice for Jones, Day, Reavis and Pogue, he was tapped by the Pharmaceutical Research and Manufacturers of America (PhRMA) to assume the No. 2 position of executive vice president of strategic and legislative affairs. He also served as an executive fellow at the American Enterprise Institute, the leading free market think tank in the U.S.

Become a Member

Please contact us if you're interested in becoming a member of SAMS.
Name(Required)